Cosentyx Gains FDA Approval for Scalp Psoriasis .pdf
Original filename: Cosentyx Gains FDA Approval for Scalp Psoriasis.pdf
Title: Cosentyx Gains FDA Approval for Scalp Psoriasis
This PDF 1.4 document has been generated by wkhtmltopdf 0.12.2.1 / Qt 4.8.6, and has been sent on pdf-archive.com on 17/06/2018 at 00:24, from IP address 76.27.x.x.
The current document download page has been viewed 228 times.
File size: 73 KB (2 pages).
Privacy: public file
Download original PDF file
Cosentyx Gains FDA Approval for Scalp Psoriasis
February 9, 2018
The FDA has approved a label update
for secukinumab (Cosentyx) for the
treatment of moderate-to-severe scalp
psoriasis, according to a Novartis press
release. Scalp psoriasis affects
approximately half of patients with psoriasis
and is notoriously difficult to treat due to the
presence of hair and other related factors.
The label will be updated in the United
States immediately, according to the release.
“Scalp psoriasis is on a very sensitive, and a
very visible area of the body. For patients this could translate into physical pain, frustration and
social isolation,” said Kristian Reich, MD, PhD, Georg-August-University Göttingen and
Dermatologikum Hamburg, Germany. “Patients and doctors are in need of effective treatment
options in this and other difficult-to-treat forms of psoriasis.”
Source: Cosentyx Gains FDA Approval for Scalp Psoriasis
thumbnail courtesy of specialtypharmacytimes.com
For more psoriasis news, check out our psoriasis news page.
Be sure to read our reviews of the best shampoo for psoriasis and the best over the counter